TY - JOUR
T1 - Antitumorigenic effect of interferon-β by inhibition of undifferentiated glioblastoma cells
AU - Yamamuro, Shun
AU - Sano, Emiko
AU - Okamoto, Yutaka
AU - Ochiai, Yushi
AU - Ohta, Takashi
AU - Ogino, Akiyoshi
AU - Natsume, Atsushi
AU - Wakabayashi, Toshihiko
AU - Ueda, Takuya
AU - Hara, Hiroyuki
AU - Nakayama, Tomohiro
AU - Yoshino, Atsuo
AU - Katayama, Yoichi
PY - 2015/11/1
Y1 - 2015/11/1
N2 - Glioma stem-like cells (GSCs) are undifferentiated cells that are considered to be an origin of glioblastomas. Furthermore, they may contribute to treatment resistance and recurrence in glioblastomas. GSCs differentiate into differentiated glioma cells (non-glioma stem-like cells: non.GSCs), and interconversion might occur between GSCs and non-GSCs. We investigated whether interferon-beta (IFN-β) could exert any efficacy towards GSCs or such interconversion processes. The neural stem cell marker CD133 and pluripotency marker Nanog in GSCs were analyzed to evaluate their differentiation levels. GSCs were considered to undergo differentiation into non-GSCs upon serum exposure, since the expression of CD133 and Nanog in the GSCs was negatively affected. Furthermore, the cells regained their undifferentiated features upon removal of the serum. However, we verified that IFN-β reduced cell proliferation and tumor sphere formation in GSCs, and induced suppression of the restoration of such undifferentiated features. In addition, we also confirmed that IFN-β suppressed the acquisition process of undifferentiated features in human malignant glioma cell lines. Our data thus suggest that IFN-β could be an effective agent not only through its cell growth inhibitory effect on GSCs but also as a means of targeting the interconversion between GSCs and non-GSCs, indicating the possibility of IFN-β being used to prevent treatment resistance and recurrence in glioblastomas, via the inhibition of undifferentiated features.
AB - Glioma stem-like cells (GSCs) are undifferentiated cells that are considered to be an origin of glioblastomas. Furthermore, they may contribute to treatment resistance and recurrence in glioblastomas. GSCs differentiate into differentiated glioma cells (non-glioma stem-like cells: non.GSCs), and interconversion might occur between GSCs and non-GSCs. We investigated whether interferon-beta (IFN-β) could exert any efficacy towards GSCs or such interconversion processes. The neural stem cell marker CD133 and pluripotency marker Nanog in GSCs were analyzed to evaluate their differentiation levels. GSCs were considered to undergo differentiation into non-GSCs upon serum exposure, since the expression of CD133 and Nanog in the GSCs was negatively affected. Furthermore, the cells regained their undifferentiated features upon removal of the serum. However, we verified that IFN-β reduced cell proliferation and tumor sphere formation in GSCs, and induced suppression of the restoration of such undifferentiated features. In addition, we also confirmed that IFN-β suppressed the acquisition process of undifferentiated features in human malignant glioma cell lines. Our data thus suggest that IFN-β could be an effective agent not only through its cell growth inhibitory effect on GSCs but also as a means of targeting the interconversion between GSCs and non-GSCs, indicating the possibility of IFN-β being used to prevent treatment resistance and recurrence in glioblastomas, via the inhibition of undifferentiated features.
KW - Differentiation
KW - Glioblastoma
KW - Glioma stem-like cells
KW - Interferon
KW - Undifferentiation
UR - http://www.scopus.com/inward/record.url?scp=84942884540&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942884540&partnerID=8YFLogxK
U2 - 10.3892/ijo.2015.3165
DO - 10.3892/ijo.2015.3165
M3 - Article
C2 - 26397698
AN - SCOPUS:84942884540
SN - 1019-6439
VL - 47
SP - 1647
EP - 1654
JO - International journal of oncology
JF - International journal of oncology
IS - 5
ER -